Management

CEO since 2015

Andreas Gerward, MSc, born 1988

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background (MSc) and a master’s in Entrepreneurship and Business Design from Chalmers University of Technology.

Holding in the Company: 600 000 shares

Chief Scientific Officer since 2015

Anders Lehmann, PhD, born 1957

Anders has broad experience in drug development from AstraZeneca with an international network, and experience from start-ups and spin-outs. Anders is an excellent project manager for preclinical and clinical development projects. Anders holds a PhD in Neurobiology from Gothenburg University and has a background in Drug Discovery research.

Holding in the Company: 90 000 shares

CFO since 2024

Erik Kullgren, MSc, born 1969

Erik Kullgren has a master’s degree in economics from the Gothenburg School of Economics and has more than 25 years of experience from finance and economics departments in various industries. His experience includes financial positions within Swedbank Robur, CFO and CEO at Dunross & Co AB and CEO at Reguity Group AB. Erik also has experience as a CFO from a listed environment through Alzinova AB, Medfield Diagnostics AB and Shortcut Media Group.

Holding in the Company: 0 shares